ABT-263 (Navitoclax)

Catalog No.S1001

ABT-263 (Navitoclax) Chemical Structure

Molecular Weight(MW): 974.61

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

  • PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

    PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    ABT-263 (Navitoclax) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    ABT-263 (Navitoclax) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M1m0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\iTWlEPTB;MD6wNFY3QSEQvF2= NHvFRphUSU6JRWK=
MV-4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVeyZoMyUUN3ME2wMlAyPTh4IN88US=> NWG5Um9PW0GQR1XS
NKM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPvNGhKSzVyPUCuNFE3QTlizszN NVjuPFBWW0GQR1XS
ML-2 NHj0TopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33OXWlEPTB;MD6wNVk5OyEQvF2= M2TmenNCVkeHUh?=
BV-173 M4HHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEKzNVQh|ryP M4D3XHNCVkeHUh?=
RS4-11 MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULBRoJyUUN3ME2wMlAzPTh5IN88US=> MoTHV2FPT0WU
HL-60 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOzXVdKSzVyPUCuNFI6ODhizszN MofjV2FPT0WU
KY821 M3rORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEK5O|Uh|ryP NYfrcmdTW0GQR1XS
ECC10 NV\IUYdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TKS2lEPTB;MD6wN|c6OiEQvF2= M13NSnNCVkeHUh?=
NCI-H720 NEDGbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfETWM2OD1yLkC0NFEyKM7:TR?= M1OzV3NCVkeHUh?=
QIMR-WIL MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;WemlEPTB;MD6wOFI5PyEQvF2= MYrTRW5ITVJ?
KG-1 NIG5Zo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvMNW1UUUN3ME2wMlA1PDh4IN88US=> MojIV2FPT0WU
TGW M1;lVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvhTWM2OD1yLkC0OlM{KM7:TR?= MoPmV2FPT0WU
ATN-1 M4f0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMES3N|Mh|ryP MljsV2FPT0WU
RH-18 NGLQVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjwXoVKSzVyPUCuNFYxPDhizszN MXvTRW5ITVJ?
EW-18 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrHW3NuUUN3ME2wMlA3QDRzIN88US=> MmnzV2FPT0WU
NB17 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETFdo5KSzVyPUCuNFcyOjRizszN M1WwbnNCVkeHUh?=
SK-NEP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP1ZmpKSzVyPUCuNFczOTNizszN NH3JSWFUSU6JRWK=
P12-ICHIKAWA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDiTWM2OD1yLkC3O|c5KM7:TR?= NGnXOJNUSU6JRWK=
KARPAS-45 NILaNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf0TY5iUUN3ME2wMlA4QDF3IN88US=> NYTNNoY4W0GQR1XS
EW-3 M3vGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDLcZFKSzVyPUCuNFgxPTNizszN M4O3c3NCVkeHUh?=
NB13 M2D4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzLSmQzUUN3ME2wMlA5OjB|IN88US=> NHrIcHhUSU6JRWK=
NCI-H209 NUH3eXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEi3NFQh|ryP NY\WbG5MW0GQR1XS
NCI-H1092 M{\6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX5eIV4UUN3ME2wMlExOjd3IN88US=> NWHx[GhYW0GQR1XS
NH-12 M3rNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMUC3OFQh|ryP M2Xn[HNCVkeHUh?=
697 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\lVoROUUN3ME2wMlExQDN7IN88US=> MXXTRW5ITVJ?
KE-37 NHjLU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITVdY1KSzVyPUCuNVE{PyEQvF2= NHrySFJUSU6JRWK=
MOLT-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTZRopCUUN3ME2wMlE2OTZ7IN88US=> MmW4V2FPT0WU
CHP-134 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLsOYxNUUN3ME2wMlE3OzB4IN88US=> MXjTRW5ITVJ?
D-283MED MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzGTWM2OD1yLkG3Olg3KM7:TR?= MlvrV2FPT0WU
LU-135 NInYVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHOTWM2OD1yLkG4OVUzKM7:TR?= NIXwdJdUSU6JRWK=
LU-134-A NHvsVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMUi2O|Eh|ryP MX;TRW5ITVJ?
EM-2 NIK0WJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMUm5NVgh|ryP MWTTRW5ITVJ?
LU-139 NIrOOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHvN2N[UUN3ME2wMlIxPDl6IN88US=> MVnTRW5ITVJ?
ALL-PO NX\lepN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrKTWM2OD1yLkKxPVg5KM7:TR?= M2nE[nNCVkeHUh?=
NB12 NUfrW2huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6RXpRUUN3ME2wMlI{OTF3IN88US=> M4DocHNCVkeHUh?=
KP-N-YN NHfid4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOydmZKSzVyPUCuNlM2PzNizszN NWDLfpNZW0GQR1XS
BEN Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\HTWM2OD1yLkKzPVY5KM7:TR?= MVXTRW5ITVJ?
HCC1569 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTkbI8{UUN3ME2wMlI2OTB4IN88US=> MkGwV2FPT0WU
HuO9 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[0XnVzUUN3ME2wMlI3PzF3IN88US=> MkW3V2FPT0WU
WM-115 NWjDZoZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f4NWlEPTB;MD6yO|c{QCEQvF2= NVLHXlVYW0GQR1XS
CCRF-CEM NWnJWnBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGwN29KSzVyPUCuN|M2OjlizszN NHfJ[nZUSU6JRWK=
IST-SL1 NWHq[G9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrCUnVKSzVyPUCuN|U{PDNizszN M3HFS3NCVkeHUh?=
BE-13 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwM{[0OVkh|ryP M3fwOXNCVkeHUh?=
COR-L88 M2jTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33IUmlEPTB;MD6zOlU1KM7:TR?= M1rZSHNCVkeHUh?=
DOHH-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHRbVVKSzVyPUCuOFExOjNizszN NFPzPHVUSU6JRWK=
A704 M{\4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHJTWM2OD1yLkSyOlch|ryP MV3TRW5ITVJ?
KNS-81-FD MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTBTWM2OD1yLkS0NFE4KM7:TR?= NVfJSmZ7W0GQR1XS
RPMI-8226 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnwNmFKSzVyPUCuOFU3PTJizszN NXPzVGU{W0GQR1XS
TGBC24TKB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:yTWM2OD1yLkS1O|c5KM7:TR?= NEju[HRUSU6JRWK=
NCI-H1304 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHIcJd[UUN3ME2wMlQ3OTV5IN88US=> MWDTRW5ITVJ?
MOLT-13 NHTrbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[1[WlEPTB;MD60OlYyOyEQvF2= NEPpRWFUSU6JRWK=
EW-22 NWHYPXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfy[2RKSzVyPUCuOFY3PzFizszN NXHxd3J7W0GQR1XS
MS-1 NVKxR2Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml74TWM2OD1yLkS2PVM{KM7:TR?= MoLoV2FPT0WU
RMG-I M{\IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNEm0OlQh|ryP NGfjXZhUSU6JRWK=
NTERA-S-cl-D1 NELtOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zONmlEPTB;MD61NFAyQSEQvF2= NWq5S|dyW0GQR1XS
NCI-H1048 NVrpVox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;qd2pKSzVyPUCuOVA6PTNizszN NEXqbmlUSU6JRWK=
SW1417 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jpSmlEPTB;MD61OVQ{QCEQvF2= M1n5dnNCVkeHUh?=
DB MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLocm9KSzVyPUCuOVcxQCEQvF2= MlPTV2FPT0WU
MEG-01 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xtb2lEPTB;MD61PFMzKM7:TR?= M33Xd3NCVkeHUh?=
EW-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL1TWM2OD1yLkW4N|QyKM7:TR?= NEHpfVdUSU6JRWK=
LAMA-84 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HCS2lEPTB;MD61PVIxPyEQvF2= MYXTRW5ITVJ?
J-RT3-T3-5 M{G5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZSGZ1UUN3ME2wMlYxQDB6IN88US=> MoS1V2FPT0WU
MOLT-16 M{PoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDHb2NWUUN3ME2wMlY2OjZ2IN88US=> NH;QNVBUSU6JRWK=
DU-4475 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PSVWlEPTB;MD62OVQzPyEQvF2= NH;WdnBUSU6JRWK=
HAL-01 M3TQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M372bGlEPTB;MD63NlU1QSEQvF2= MVvTRW5ITVJ?
RD NILzWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTxTWM2OD1yLke1PFk6KM7:TR?= MXHTRW5ITVJ?
OAW-28 MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHXTWM2OD1yLke4N|ch|ryP MkPOV2FPT0WU
HCC38 NGfvNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjV[IxQUUN3ME2wMlgxOTlizszN M3nzXHNCVkeHUh?=
NMC-G1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwOEGxNlEh|ryP NHLYV|dUSU6JRWK=
EW-16 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fnN2lEPTB;MD64NVMzQCEQvF2= MV;TRW5ITVJ?
DU-145 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHRcY9KSzVyPUCuPFk6OjNizszN NYDxRpA2W0GQR1XS
HPAF-II MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPFTWM2OD1yLkmyOlI5KM7:TR?= MXTTRW5ITVJ?
A427 NXXpfVhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf6XVdMUUN3ME2wMlk{ODJ{IN88US=> NWn5THpSW0GQR1XS
PA-1 M2K5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPtcpFmUUN3ME2wMlk2PjR{IN88US=> NGDsflNUSU6JRWK=
OAW-42 NELiToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrhZnJXUUN3ME2wMlk3OTR4IN88US=> MX;TRW5ITVJ?
L-428 NFThdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwMEGyOUDPxE1? MUjTRW5ITVJ?
COLO-824 NFHTTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XJUmlEPTB;MT6wNVcxQCEQvF2= M1jKSnNCVkeHUh?=
P30-OHK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LOOWlEPTB;MT6wOFY5QCEQvF2= MYnTRW5ITVJ?
NCI-H2170 NWfObWJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonITWM2OD1zLkC2NlMh|ryP M4rkUXNCVkeHUh?=
HCC2998 M{jwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\QTmlEPTB;MT6wO|E{PSEQvF2= NGnCc4VUSU6JRWK=
NB14 NIW2OmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwMUO3OFgh|ryP MYTTRW5ITVJ?
TGBC1TKB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml76TWM2OD1zLkG0NVUzKM7:TR?= MYDTRW5ITVJ?
KP-N-YS MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tr[mlEPTB;MT6xOlI{PiEQvF2= MXvTRW5ITVJ?
CAL-120 M3H0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXTWM2OD1zLkG2OFI6KM7:TR?= M4\VUnNCVkeHUh?=
SBC-1 NV3xb4U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpTWM2OD1zLkG5NFU{KM7:TR?= Ml:5V2FPT0WU
C32 NX33SIZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTmTWM2OD1zLkG5NFg5KM7:TR?= MYLTRW5ITVJ?
HCC2157 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvmTWM2OD1zLkG5OFk1KM7:TR?= MmWzV2FPT0WU
COLO-792 M2\XPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnLUHBlUUN3ME2xMlIxODdzIN88US=> MUPTRW5ITVJ?
ES7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv5TWM2OD1zLkK3PVUyKM7:TR?= MmPmV2FPT0WU
HEL NVTte41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfxdmZKSzVyPUGuN|ExOjlizszN M4G2[nNCVkeHUh?=
ES4 NEGyO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DHdGlEPTB;MT6zOFk6QCEQvF2= NVj1PZB[W0GQR1XS
NCI-SNU-1 NH71eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C4R2lEPTB;MT6zOlU2PSEQvF2= NX;sR3ZzW0GQR1XS
MDA-MB-415 NH7ZepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS4XHFYUUN3ME2xMlM5QDVizszN NX\KOFFGW0GQR1XS
NCI-H2342 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi2SWZKSzVyPUGuOFAzPjlizszN MYHTRW5ITVJ?
NB69 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PuSWlEPTB;MT60OlI4OSEQvF2= M2XaTnNCVkeHUh?=
D-247MG NWHPV5Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LpbGlEPTB;MT61NVEzOiEQvF2= NWi3XGd[W0GQR1XS
SCC-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zFdmlEPTB;MT61PVg5PyEQvF2= MofvV2FPT0WU
HuH-7 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG1TWM2OD1zLk[3Nlk{KM7:TR?= M{H0PXNCVkeHUh?=
A388 NVKwdFJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzub2RKSzVyPUGuOlg4OjRizszN MWfTRW5ITVJ?
Calu-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Pk[mlEPTB;MT63NFY6PyEQvF2= M1j0ZXNCVkeHUh?=
NCI-H1648 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrFTWM2OD1zLkexOFE5KM7:TR?= NV;SV4tVW0GQR1XS
NCI-H2052 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XDeGlEPTB;MT63NlIxOSEQvF2= NIfvbnJUSU6JRWK=
Ramos-2G6-4C10 NHLob5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnLTWM2OD1zLkezOlU3KM7:TR?= NVLDXHFwW0GQR1XS
DEL M{HkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHh[|N4UUN3ME2xMlc1Pjl{IN88US=> NFrNSlFUSU6JRWK=
SNU-423 NHrLNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jFVmlEPTB;MT63PFE2PyEQvF2= NEj3Um1USU6JRWK=
COR-L23 NHPYT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\0TWM2OD1zLke5PFc1KM7:TR?= NYr4dXI1W0GQR1XS
OMC-1 NHe5cY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwOE[wNVYh|ryP MlvhV2FPT0WU
EW-11 M3XiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvMfoZKSzVyPUGuPVU3PTdizszN MoTXV2FPT0WU
HSC-3 M175cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfVTWM2OD1zLkm2N|Y2KM7:TR?= NIixSoRUSU6JRWK=
MLMA NX25WVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HjbmlEPTB;MT65OlY4PyEQvF2= MoLKV2FPT0WU
RCM-1 NUXHRlhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrKfXhiUUN3ME2yMlAxOzl7IN88US=> MXjTRW5ITVJ?
MFE-280 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwMEK4OFgh|ryP MWrTRW5ITVJ?
ES8 M2nlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJwMkW0O|Eh|ryP MnnvV2FPT0WU
TE-11 NV\Vb|cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fXR2lEPTB;Mj6yPVQ4OyEQvF2= MmDQV2FPT0WU
HuO-3N1 NI[4XVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPmTWM2OD1{LkS4O|gh|ryP MYPTRW5ITVJ?
MHH-NB-11 M2\ldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr6TWM2OD1{LkWxNVU5KM7:TR?= MmP0V2FPT0WU
TGBC11TKB NHLp[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M120emlEPTB;Mj61O|Y5OSEQvF2= NEXaOYdUSU6JRWK=
HOP-92 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnjTWM2OD1{LkW4O|Q{KM7:TR?= MWDTRW5ITVJ?
IGR-1 NHrufYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjXdWVoUUN3ME2yMlYzODN3IN88US=> NYjBfXFZW0GQR1XS
GOTO NHexOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfQc2RpUUN3ME2yMlY2Ozd5IN88US=> NXjFfHhDW0GQR1XS
NCI-H1650 NFjZc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PPV2lEPTB;Mj63NlIyPSEQvF2= NE\BSXBUSU6JRWK=
NCI-H1581 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\XZ2lEPTB;Mj63PVY5OSEQvF2= MnvHV2FPT0WU
NCI-H2405 NEjKRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLJTWM2OD1{LkiyO|gzKM7:TR?= NFL3NphUSU6JRWK=
U-118-MG NY\ObVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LuXWlEPTB;Mj65OlQ6OSEQvF2= M4PyWnNCVkeHUh?=
DoTc2-4510 NYewTZFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf4VmlKSzVyPUOuNFE1OTdizszN MoKwV2FPT0WU
NCI-H596 NVfyZYt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzFTWM2OD1|LkC0PVk4KM7:TR?= MlrHV2FPT0WU
MPP-89 NVHTPJRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNwMEW2OlYh|ryP M3HiNnNCVkeHUh?=
GCIY NVXLT5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNwMkC0PVEh|ryP MXfTRW5ITVJ?
SW626 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLEfnVKSzVyPUOuNlQ2PDNizszN MVzTRW5ITVJ?
OCI-AML2 NYX1SFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\HOIxSUUN3ME2zMlMyOjd{IN88US=> M1jwRnNCVkeHUh?=
NBsusSR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPySI5KUUN3ME2zMlM1QTN6IN88US=> Ml7VV2FPT0WU
AN3-CA NWrUVpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPB[pdKSzVyPUOuOFQzOzhizszN NYrpZXdwW0GQR1XS
EFM-19 NG\MZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LTZWlEPTB;Mz60PFM{QSEQvF2= MnTBV2FPT0WU
RVH-421 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnD[Fh4UUN3ME2zMlU3QDd5IN88US=> NIXlW2hUSU6JRWK=
5637 M1jMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDn[HZKSzVyPUOuOlEyODNizszN M3LUbXNCVkeHUh?=
PANC-08-13 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwNkO0O|Ih|ryP NHO2eYJUSU6JRWK=
H9 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOwTWM2OD1|Lk[3NVQ1KM7:TR?= NUP4PIlIW0GQR1XS
KARPAS-299 M1LUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwNkezOlEh|ryP NYHJTGVIW0GQR1XS
TE-5 M1L5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\Td5hKSzVyPUOuO|A4ODlizszN MlTEV2FPT0WU
NOS-1 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\3TWM2OD1|Lke5PFM1KM7:TR?= MmnuV2FPT0WU
HH MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe1e2ZKSzVyPUOuPFM5PjhizszN M1fWbHNCVkeHUh?=
769-P M2DqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHkU3F7UUN3ME2zMlg6PTFizszN MUnTRW5ITVJ?
CHP-212 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNwOUK1OFkh|ryP Mne1V2FPT0WU
NCI-H82 NVm1[lhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n3N2lEPTB;Mz65OVk{PiEQvF2= MmL3V2FPT0WU
Mo-T MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn2PXhYUUN3ME20MlA1OzF{IN88US=> MYDTRW5ITVJ?
BB65-RCC MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7Rc|VKSzVyPUSuNFQ{QTlizszN MVjTRW5ITVJ?
SW1990 NVPhN|lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jpbWlEPTB;ND6wOVkxQCEQvF2= NV3kSYRPW0GQR1XS
LK-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzmcIhKSzVyPUSuNVEzQTNizszN MlTqV2FPT0WU
ES5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwMUO5PFUh|ryP Ml7XV2FPT0WU
JVM-3 NWL5fYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwMUiyNlIh|ryP MX;TRW5ITVJ?
RPMI-7951 NVr3ZplIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInxNodKSzVyPUSuNlI1OTNizszN MXPTRW5ITVJ?
Calu-6 NIf6cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDOWlEPTB;ND6yO|g5OSEQvF2= MmT4V2FPT0WU
LC-2-ad NF7jUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLmUYRFUUN3ME20MlI6PTZ6IN88US=> MnvZV2FPT0WU
SW954 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnpd3hKSzVyPUSuNlk3PiEQvF2= MlH0V2FPT0WU
H-EMC-SS M1u5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Hcm9KSzVyPUSuN|E5OzFizszN NH;BVoNUSU6JRWK=
ES3 NHHUW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL0ZmRKSzVyPUSuN|U1PDFizszN MVfTRW5ITVJ?
no-11 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRwM{W1OVQh|ryP NHTC[|RUSU6JRWK=
LAN-6 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ZTWM2OD12LkS1NVg6KM7:TR?= MkPCV2FPT0WU
FTC-133 M3LsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\qR5hKSzVyPUSuOVM6PSEQvF2= M2XFPXNCVkeHUh?=
8505C MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WzTGlEPTB;ND61OFI{KM7:TR?= MVjTRW5ITVJ?
SW620 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OzTmlEPTB;ND61O|A2PyEQvF2= MVLTRW5ITVJ?
BCPAP NGfKUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17T[2lEPTB;ND62N|Q5OSEQvF2= NWPQTY1MW0GQR1XS
SK-LU-1 NXi0cW9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\RRYVKSzVyPUSuOlYxQDlizszN NFy5eXlUSU6JRWK=
NCI-H1623 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq2TWM2OD12LkewNlI5KM7:TR?= NFPxbmVUSU6JRWK=
C2BBe1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfOXVNKSzVyPUSuO|QxODhizszN Mn\wV2FPT0WU
GP5d MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTTTWM2OD12Lke4N|g5KM7:TR?= MmLCV2FPT0WU
NB6 NHH5d4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm0VmZKSzVyPUSuPFYzODRizszN NY\kfW94W0GQR1XS
MDA-MB-157 M3;CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLTWM2OD12Lki4O|Yh|ryP NEjZXJRUSU6JRWK=
UMC-11 NIfjR|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\MVYxQUUN3ME20Mlg5QTZ2IN88US=> M4fWfHNCVkeHUh?=
HCC1419 NYrXOFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwOUCwOlMh|ryP MlH6V2FPT0WU
NCI-H2029 M33GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3WUZFKSzVyPUSuPVQyQDVizszN MoD2V2FPT0WU
LXF-289 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrDXVVKSzVyPUWuNFM4OTlizszN MUDTRW5ITVJ?
KINGS-1 NUjR[VNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGybnZKSzVyPUWuNFc4PDRizszN NI\BPIFUSU6JRWK=
HD-MY-Z NEjndmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTVwMkO5Olkh|ryP NVv6[2tzW0GQR1XS
ESS-1 M3rk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLa[mlKSzVyPUWuNlU2QTdizszN MX\TRW5ITVJ?
GI-1 M360[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfHe2VKSzVyPUWuNlc6OjZizszN MWPTRW5ITVJ?
RPMI-2650 NFjW[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D0dmlEPTB;NT6zOlE3KM7:TR?= M1XlcHNCVkeHUh?=
IA-LM M1O4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HhbmlEPTB;NT6zPVg4OSEQvF2= NYm1UJh1W0GQR1XS
KP-4 NIr2OYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTVwNE[zN|Qh|ryP MXrTRW5ITVJ?
G-402 NHHtWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ETWM2OD13LkWxPFY2KM7:TR?= MULTRW5ITVJ?
OS-RC-2 NHLjOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L2PGlEPTB;NT61NlYxPCEQvF2= M1niNHNCVkeHUh?=
NCI-H1155 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37sU2lEPTB;NT61OFk2PSEQvF2= NXftZWI{W0GQR1XS
OE19 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX2TWM2OD13Lk[4OlI1KM7:TR?= MnvtV2FPT0WU
U-2-OS M{HiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rOdGlEPTB;NT64PVAyOyEQvF2= NX\2RXFEW0GQR1XS
SCC-15 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXidZRSUUN3ME21Mlk{PjZ{IN88US=> MXHTRW5ITVJ?
NCI-H630 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLjTWM2OD13Lkm5OFA1KM7:TR?= M1nXfXNCVkeHUh?=
PFSK-1 NYLnVWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK0TWM2OD14LkC1NlU6KM7:TR?= M2DyXXNCVkeHUh?=
NCI-H1770 M1\Cdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTZwMkC4O|Qh|ryP NELHU5ZUSU6JRWK=
SK-MEL-3 MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTZwNEK5NVUh|ryP MYTTRW5ITVJ?
LB1047-RCC M2rxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXwXnBMUUN3ME22MlQ4PjJ3IN88US=> NUnQR2RVW0GQR1XS
NCI-H446 NYfhdphrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXpbWpKSzVyPU[uOlI6OjVizszN MYHTRW5ITVJ?
SW780 NYHBOY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTZwN{CxPFUh|ryP MojUV2FPT0WU
NEC8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTZwN{[2N{DPxE1? MYXTRW5ITVJ?
NOMO-1 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jG[GlEPTB;Nj63PFEyOSEQvF2= NXPrW2NHW0GQR1XS
COLO-668 M3LaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\BZmlEPTB;Nj64OFM5PyEQvF2= NX3YZo5IW0GQR1XS
MC116 NXPwe3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i0WWlEPTB;Nj65N|g6PyEQvF2= NXPnZ25oW0GQR1XS
HCC1937 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LOW2lEPTB;Nj65PVI2OSEQvF2= NUPHZYo1W0GQR1XS
NCI-N87 M2P1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTdwMUmyPVMh|ryP Mkf5V2FPT0WU
COLO-320-HSR M2PjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdwMkK3N|gh|ryP MY\TRW5ITVJ?
HCC1806 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\pTWM2OD15LkK2NFQ1KM7:TR?= M4nte3NCVkeHUh?=
OVCAR-3 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zVPWlEPTB;Nz6zN|A{QCEQvF2= NVT0dYNUW0GQR1XS
NUGC-3 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrUXGFDUUN3ME23MlM6Pjl2IN88US=> M3\KeXNCVkeHUh?=
SW1783 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjhPJJKSzVyPUeuOFMyPzVizszN NYH2Z3ZbW0GQR1XS
GCT M1XwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrkU4lKSzVyPUeuOVY6ODZizszN NXXhe3ZIW0GQR1XS
NCI-H2126 NVXofpNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\RT2hjUUN3ME23Mlc{PjJ3IN88US=> MnfGV2FPT0WU
MEL-HO NHrUdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfjO45KSzVyPUeuO|cxPTRizszN MYXTRW5ITVJ?
CAPAN-1 NXfDOnZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdwN{ezOVch|ryP MXTTRW5ITVJ?
SW756 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGiy[ZNKSzVyPUeuO|g{OzNizszN M4PxZXNCVkeHUh?=
SKG-IIIa M{TrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj5dmJNUUN3ME23MlgyQDl{IN88US=> MWTTRW5ITVJ?
HCE-T M4TDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTdwOEe3PFMh|ryP NWe4THg5W0GQR1XS
Ca-Ski M{C5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTdwOUmzPFMh|ryP NXKyT2lLW0GQR1XS
COLO-684 NHHTNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XNXWlEPTB;OD6wNVgyQCEQvF2= NUj0PJBOW0GQR1XS
KYSE-70 M{S1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrjZ5hKSzVyPUiuNFc4OjlizszN MWfTRW5ITVJ?
TI-73 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnKc4JKSzVyPUiuNlU5PTFizszN NF7zOW5USU6JRWK=
BT-20 NEPD[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HiR2lEPTB;OD6yOlA2OiEQvF2= M2XLSXNCVkeHUh?=
MHH-ES-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LZd2lEPTB;OD61NVg{PCEQvF2= NEnJV4lUSU6JRWK=
TE-12 NYq2bVZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;hfpQ3UUN3ME24MlU6QTNzIN88US=> MofOV2FPT0WU
YH-13 M1TvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfZVGdKSzVyPUiuOlExODhizszN MXvTRW5ITVJ?
SF126 M2fufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HhNGlEPTB;OD64N|g3PSEQvF2= NUjJZlY5W0GQR1XS
J82 M3zCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jIVGlEPTB;OD65NFA{QCEQvF2= NUK2UpNxW0GQR1XS
RCC10RGB MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zWVWlEPTB;OD65PVU3OSEQvF2= MUXTRW5ITVJ?
SK-UT-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPBW5NKSzVyPUmuNFQ6PDVizszN M1LHXnNCVkeHUh?=
LB2241-RCC NGrrRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTlwMUmxN|ch|ryP Ml;mV2FPT0WU
LB996-RCC M3jqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ZbmlEPTB;OT6xPVg6KM7:TR?= M2PONXNCVkeHUh?=
EPLC-272H MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[4[2lEPTB;OT6zO|Y2PyEQvF2= MlfRV2FPT0WU
CTV-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfJeWRUUUN3ME25MlU3PTN{IN88US=> M{nh[3NCVkeHUh?=
HSC-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULnXoF5UUN3ME25MlU4PTVizszN MlHvV2FPT0WU
SK-MEL-28 NYGwPII3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTlwNkG4PVMh|ryP M{jrPHNCVkeHUh?=
MMAC-SF NVnscY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTlwNki3OUDPxE1? NUDySo5zW0GQR1XS
CP50-MEL-B M3\zPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;v[oVkUUN3ME25Mlc2Pzh{IN88US=> MXTTRW5ITVJ?
HT-1080 NHm3UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq4NFZxUUN3ME25Mlc4PzN7IN88US=> NVL5NXNqW0GQR1XS
HEC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\wTWM2OD1zMD6zN|UzKM7:TR?= MXXTRW5ITVJ?
AGS M1;LcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjzUlNKSzVyPUGwMlM4PCEQvF2= NGfDbItUSU6JRWK=
GAMG NHL5fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFyLkWxOlIh|ryP M2mwU3NCVkeHUh?=
SW48 M1W3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPNXFJqUUN3ME2xNE42OTh7IN88US=> NIPyPGVUSU6JRWK=
U031 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu0c4dKSzVyPUGwMlU6ODhizszN MmjVV2FPT0WU
OVCAR-5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFyLk[0Nlkh|ryP MnLBV2FPT0WU
SF295 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj5TWM2OD1zMD62O|A1KM7:TR?= M3O1SHNCVkeHUh?=
BHT-101 Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\GTWM2OD1zMD63NVc4KM7:TR?= NXjqOZA4W0GQR1XS
VMRC-RCZ NVzvPJFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHYUHZKSzVyPUGxMlMzODFizszN MoK0V2FPT0WU
ACHN NV2zRVgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTCZlRJUUN3ME2xNU41OjFzIN88US=> MVLTRW5ITVJ?
NCI-H526 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VVWlEPTB;MUGuOVA1OyEQvF2= M{PyZ3NCVkeHUh?=
MN-60 M3rmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFzLkWzPUDPxE1? MUfTRW5ITVJ?
NCI-H2291 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITlco1KSzVyPUGxMlU1PjZizszN NWHDU4djW0GQR1XS
SCC-25 NVv4V3RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFzLke1OVYh|ryP MojQV2FPT0WU
SK-MEL-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO4TmNKSzVyPUGxMlc3OzdizszN MXrTRW5ITVJ?
SN12C M{DZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L0SmlEPTB;MUGuPVM2PSEQvF2= NEXy[pNUSU6JRWK=
NCI-H69 NWPTe|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEiydZFKSzVyPUGyMlQzOzRizszN M3njOnNCVkeHUh?=
ME-180 NVjjVmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF{LkewOVQh|ryP M1;McnNCVkeHUh?=
MC-IXC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPqTWM2OD1zMj63OVE5KM7:TR?= M3zBeXNCVkeHUh?=
NCI-H2347 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3mTWM2OD1zMj63OlE1KM7:TR?= MVXTRW5ITVJ?
M059J NULCWWM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTCUFMyUUN3ME2xNk44PzJ5IN88US=> NGrCWnVUSU6JRWK=
A2058 M1nKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfM[VZvUUN3ME2xNk45PjhzIN88US=> NXvac2RiW0GQR1XS
VA-ES-BJ NVe2U3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF{Lki3PFUh|ryP M1fVR3NCVkeHUh?=
Ca9-22 NVLTOnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zHTGlEPTB;MUKuPVQ2OSEQvF2= NYXCbIFtW0GQR1XS
KNS-42 NFLZdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;6UWlEPTB;MUKuPVk5PCEQvF2= M3\y[3NCVkeHUh?=
LoVo MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nUTGlEPTB;MUOuNlMyOyEQvF2= NIP4UVBUSU6JRWK=
AM-38 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;lSFFFUUN3ME2xN{4zPTZ4IN88US=> NX:0[5VIW0GQR1XS
NB5 M4XhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13MSWlEPTB;MUOuN|c2OiEQvF2= M3joUnNCVkeHUh?=
L-363 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECxWoxKSzVyPUGzMlQxOzNizszN NXXQTmJRW0GQR1XS
SK-MEL-30 NEPYd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXqTWM2OD1zND6wOlQ2KM7:TR?= M4HuSXNCVkeHUh?=
NCI-H1563 NFXMVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF2Lk[wN|kh|ryP M4rKWHNCVkeHUh?=
NCI-H2228 NYDNc29OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW3VHlKSzVyPUG0MlYxPzdizszN NFLNS2ZUSU6JRWK=
MFM-223 NE[0R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF3LkG4NVMh|ryP NIXxc|NUSU6JRWK=
LB831-BLC NVHJ[nR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DVeWlEPTB;MUWuNlc3PyEQvF2= NHS2U|lUSU6JRWK=
SW872 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjWTWM2OD1zNT6zNFg3KM7:TR?= NIH0bHpUSU6JRWK=
NCI-H522 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTtZ4dHUUN3ME2xOU4{OzB4IN88US=> MV\TRW5ITVJ?
EW-1 NXLjTVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULveppbUUN3ME2xOU42PDZ{IN88US=> MW\TRW5ITVJ?
HN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXsTWM2OD1zNT61PVQzKM7:TR?= MmfhV2FPT0WU
SW837 M4K2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTJTWM2OD1zNT63PFQ4KM7:TR?= MnTwV2FPT0WU
SCC-9 M4rSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\uVnhKSzVyPUG1MlgyOTRizszN NXjaXHBZW0GQR1XS
MKN7 NGHkc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPpTWM2OD1zNT65O|MzKM7:TR?= NWe2dXZLW0GQR1XS
KYSE-410 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP6XmJKSzVyPUG2MlU6OSEQvF2= Mn\DV2FPT0WU
SK-N-DZ NHzs[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HtT2lEPTB;MU[uOlEyPiEQvF2= MlXsV2FPT0WU
COR-L105 MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInhZ2FKSzVyPUG2MlY2OjhizszN MlTCV2FPT0WU
LB2518-MEL NEC5[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOxTWM2OD1zNj64N|g6KM7:TR?= M1LIU3NCVkeHUh?=
OVCAR-4 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qxO2lEPTB;MU[uPFg3OiEQvF2= MomxV2FPT0WU
TK10 M1jocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL4TWM2OD1zNj65OFc{KM7:TR?= M4HNWXNCVkeHUh?=
KNS-62 NGnvVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLpPW9KSzVyPUG2Mlk4PzdizszN Mo\5V2FPT0WU
RPMI-8866 M3PuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX6V|RKSzVyPUG3MlE4OzJizszN M2TrdHNCVkeHUh?=
HuP-T4 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17xfmlEPTB;MUeuNlQ6PSEQvF2= MkfsV2FPT0WU
CGTH-W-1 M2\MRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TTXWlEPTB;MUeuOVIyQSEQvF2= MYDTRW5ITVJ?
T-24 NFntd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF5LkWzOFch|ryP M2LzcnNCVkeHUh?=
HT-3 NVntVGczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXFeJFEUUN3ME2xO{42QTF2IN88US=> MWDTRW5ITVJ?
KS-1 M1nzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF5Lk[3N{DPxE1? NHnI[4NUSU6JRWK=
NCI-H1792 NH;oPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfhXnBKSzVyPUG3Mlc6QCEQvF2= Mlm4V2FPT0WU
ABC-1 NUPK[FR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTVZZA4UUN3ME2xO{45OTRzIN88US=> MkDEV2FPT0WU
BPH-1 NVH5UFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF6LkG2PFUh|ryP MWLTRW5ITVJ?
A431 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP0e49mUUN3ME2xPE41OTJ5IN88US=> MnnnV2FPT0WU
T98G NELCOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF6LkWxOVch|ryP M1u5b3NCVkeHUh?=
BHY M2PxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD1zOD64Olkh|ryP M2q3TnNCVkeHUh?=
Capan-2 NUfBZY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjk[XlKSzVyPUG4MlkxPzhizszN M13wbnNCVkeHUh?=
MDA-MB-175-VII M1fhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF6LkmyNFkh|ryP MWjTRW5ITVJ?
CAL-27 NH75dIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLvTWM2OD1zOT6wOFg4KM7:TR?= MkjsV2FPT0WU
AsPC-1 NEnoSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF7Lki2OVch|ryP MnfWV2FPT0WU
KU812 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\vTWM2OD1zOT65OVc{KM7:TR?= MoLyV2FPT0WU
NCI-H441 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlznTWM2OD1{MD6wNFEh|ryP M{\xfHNCVkeHUh?=
Mewo MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH5RXZ7UUN3ME2yNE4yOjh6IN88US=> M2DrUXNCVkeHUh?=
SK-MEL-24 NEHMPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;qVmlEPTB;MkCuNVQ4PyEQvF2= MV;TRW5ITVJ?
NCI-H727 NH;qT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\KfGlEPTB;MkCuNlcxPCEQvF2= MkjHV2FPT0WU
EKVX NUC4dXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r6[2lEPTB;MkCuOlA3KM7:TR?= NFf5NG1USU6JRWK=
RT-112 M{DFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJyLk[xNlIh|ryP MlXSV2FPT0WU
CAMA-1 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL0UppKSzVyPUKwMlk5ODNizszN MXHTRW5ITVJ?
SW900 NXv6NGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJzLkCxOFkh|ryP MXzTRW5ITVJ?
NCI-H23 NWHWTm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrpTWM2OD1{MT6xNlc4KM7:TR?= NULPOZNwW0GQR1XS
SK-PN-DW NWHxdXNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJzLkG2OFkh|ryP NEX6fVVUSU6JRWK=
BB30-HNC NYf2RppCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJzLkK3OFUh|ryP NFXxN2FUSU6JRWK=
VM-CUB-1 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj6VmRHUUN3ME2yNU4{PTN4IN88US=> NETmfIZUSU6JRWK=
IST-MEL1 NIrvdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJzLkO2PVIh|ryP MlO1V2FPT0WU
CTB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULPRWJQUUN3ME2yNU41PzV3IN88US=> MUfTRW5ITVJ?
LCLC-103H NHnjelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf5cHRKSzVyPUKyMlE2QDJizszN MWDTRW5ITVJ?
PANC-03-27 NWnHcWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\sTphKSzVyPUKyMlUyPjlizszN M{XsNnNCVkeHUh?=
HTC-C3 M4\3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLqcWg3UUN3ME2yNk42PTV3IN88US=> MYDTRW5ITVJ?
TE-8 M4m2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfrUZJKSzVyPUKzMlI2PjVizszN NIPS[Y9USU6JRWK=
NCI-H292 M1Hvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzkTWM2OD1{NT6zOVM3KM7:TR?= NEjQdVBUSU6JRWK=
COLO-680N MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTWeVV3UUN3ME2yOU43OzJ7IN88US=> MmXZV2FPT0WU
KYSE-520 NIX6SHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ3Lk[0OEDPxE1? MUfTRW5ITVJ?
NB10 M2q2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLQTWM2OD1{Nj6zNVE4KM7:TR?= NUjBU5J1W0GQR1XS
NCI-H661 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rXWGlEPTB;Mk[uOFcyOyEQvF2= MofBV2FPT0WU
GMS-10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTBUWhGUUN3ME2yOk45PjN6IN88US=> MWrTRW5ITVJ?
NCI-H2122 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlfXRKSzVyPUK2Mlk6QThizszN NYDD[2NpW0GQR1XS
OVCAR-8 M3LZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ5LkC2N|gh|ryP MUXTRW5ITVJ?
DJM-1 M3nBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILSe2NKSzVyPUK3MlE1PTRizszN MVfTRW5ITVJ?
UACC-893 NF3DU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrwboZKSzVyPUK3Mlk5PzhizszN MUXTRW5ITVJ?
C8166 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzYXplKSzVyPUK4MlY6OzhizszN NHPyOpNUSU6JRWK=
NCI-H1693 M{X2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf5TWM2OD1{OD62PVc2KM7:TR?= NVf5UoZKW0GQR1XS
TYK-nu M{K0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmxdHNSUUN3ME2zNE4xOzR3IN88US=> NH7vWoNUSU6JRWK=
SW1710 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNyLkGyOkDPxE1? NHPw[YxUSU6JRWK=
A375 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TKR2lEPTB;M{CuN|I1OyEQvF2= MmHTV2FPT0WU
HMV-II NH:1co1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W5VGlEPTB;M{GuN|U6OiEQvF2= MUfTRW5ITVJ?
NCI-H2087 M1PxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS3OnNKSzVyPUOxMlY{PTJizszN NVzzUVIzW0GQR1XS
CAL-54 NF7v[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL4dWdIUUN3ME2zNU44OjRzIN88US=> M1PXZnNCVkeHUh?=
HCC70 NXHzeIZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf1TWM2OD1|Mj6xN|g4KM7:TR?= MUfTRW5ITVJ?
ES1 M3foNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TtWGlEPTB;M{KuN|A3OiEQvF2= MoHLV2FPT0WU
NCI-H1355 M3vJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC5dlRKSzVyPUOzMlIxPCEQvF2= NXm5WHBCW0GQR1XS
CFPAC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\oVJpKSzVyPUOzMlI{OzJizszN NV\rUVlnW0GQR1XS
MKN28 M2fwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTN|LkO4NFkh|ryP NVrwcVh5W0GQR1XS
HDLM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7PenFMUUN3ME2zN{43QTNzIN88US=> NGLJVIhUSU6JRWK=
PANC-10-05 NYGzS4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlflTWM2OD1|ND6xNFE1KM7:TR?= MVPTRW5ITVJ?
SAS M4jYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTN2LkS1OlUh|ryP NULoZ3A4W0GQR1XS
HCC1395 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTN2LkexPFYh|ryP M{fDbHNCVkeHUh?=
8305C NUHKbnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[yVGlEPTB;M{WuPFQyPSEQvF2= NIX3T25USU6JRWK=
KM12 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnkTohqUUN3ME2zOk44PTR5IN88US=> NVXBR41TW0GQR1XS
SW1116 NULReY5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL2fFFtUUN3ME2zO{42QTl{IN88US=> NIjHbmZUSU6JRWK=
SK-MEL-1 NIjq[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjXTWM2OD1|OD6zN|g6KM7:TR?= MWTTRW5ITVJ?
HCC2218 NGPZdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O2bmlEPTB;M{iuOlUyQSEQvF2= NWGwemFuW0GQR1XS
T84 M333dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHvSpJKSzVyPUO4Mlc1ODlizszN MUXTRW5ITVJ?
ETK-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjWW|BKSzVyPUO5MlAzOiEQvF2= NXniZmpJW0GQR1XS
COLO-800 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfObFVKSzVyPUO5MlM5PjhizszN M3zRWXNCVkeHUh?=
CAL-12T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO5bmxKSzVyPUO5MlUzQDFizszN M2HLZXNCVkeHUh?=
ACN MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRyLkS5NVEh|ryP M2i5VHNCVkeHUh?=
SJSA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRzLkG1PVYh|ryP MnLnV2FPT0WU
PSN1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXyTWM2OD12MT6xO|Q6KM7:TR?= NHHjNZhUSU6JRWK=
D-566MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[0OmlEPTB;NEGuNlA5PiEQvF2= MX7TRW5ITVJ?
EGI-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm2VndUUUN3ME20Nk41OjhizszN MYPTRW5ITVJ?
A204 Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrhNVJKSzVyPUSyMlY{QDhizszN M1vaUXNCVkeHUh?=
Saos-2 NXzNPZdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm0bYdNUUN3ME20Nk45OzZ7IN88US=> Mn;5V2FPT0WU
SNU-C2B NFy5PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX4b|BUUUN3ME20N{43QDd6IN88US=> MlTWV2FPT0WU
HLE MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHIPYZtUUN3ME20OE4xQDV4IN88US=> M4DjdXNCVkeHUh?=
SW1463 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fPN2lEPTB;NESuPVk4OSEQvF2= NWnnRZdqW0GQR1XS
DSH1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTR3LkCwN|Mh|ryP MVTTRW5ITVJ?
MCF7 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvtUWJqUUN3ME20OU42ODVzIN88US=> NF[zXohUSU6JRWK=
K5 M{nicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfndJdKSzVyPUS1Mlk1ODVizszN MlvaV2FPT0WU
NCI-H358 NHrsSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TaO2lEPTB;NEeuNlE2KM7:TR?= MXLTRW5ITVJ?
NCI-H2030 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTR5LkKzO|Qh|ryP MYHTRW5ITVJ?
SW948 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[5TWM2OD12Nz60OlQh|ryP M2DON3NCVkeHUh?=
BALL-1 M{SyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PZbWlEPTB;NEeuOlE3QCEQvF2= M{nNcHNCVkeHUh?=
TE-9 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\NTWM2OD12Nz65OVgyKM7:TR?= NGK1dIFUSU6JRWK=
SK-N-FI MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT3[45LUUN3ME20PE4xOzV6IN88US=> MlvsV2FPT0WU
KALS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR6LkGyPFkh|ryP MXHTRW5ITVJ?
HO-1-N-1 NFXneHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzUTWM2OD12OD63OFQ2KM7:TR?= MVvTRW5ITVJ?
NCI-H2452 NV\EeXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTR7LkGxOVIh|ryP MnjWV2FPT0WU
OC-314 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PoXGlEPTB;NEmuOlg{PCEQvF2= NF7tXmxUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay
+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research
+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+corn oil 7mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Suspended Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Solid Neoplasm|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-263 (Navitoclax) | ABT-263 (Navitoclax) supplier | purchase ABT-263 (Navitoclax) | ABT-263 (Navitoclax) cost | ABT-263 (Navitoclax) manufacturer | order ABT-263 (Navitoclax) | ABT-263 (Navitoclax) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID